A new peer-reviewed study published in the Journal of the American College of Cardiology is taking a closer look at how GLP-1 receptor agonists — the drug class behind Ozempic and Wegovy — stack up against SGLT2 inhibitors for heart protection in people with type 2 diabetes. The findings matter because millions of patients and their doctors must choose between these two drug classes.
Why This Comparison Matters
Both GLP-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have well-established cardiovascular benefits for people with type 2 diabetes. Previous research has generally found similar class-level effectiveness between the two groups, meaning that as broad categories, neither appeared dramatically superior to the other.
However, the new study points out a critical gap: real-world comparative effectiveness data on individual agents within each class remains limited. That distinction is important, because not all GLP-1 drugs are identical, and not all SGLT2 inhibitors are identical — yet patients and clinicians are often making medication decisions as if they were interchangeable.
What the Study Set Out to Do
Rather than relying solely on randomized controlled trials — which test drugs under tightly controlled conditions — this research focuses on real-world effectiveness. That approach reflects how these medications actually perform across diverse patient populations, different dosing practices, and varying levels of adherence. The study was published in the Journal of the American College of Cardiology, one of the most prominent cardiology journals in the world, lending the research significant credibility.
Both GLP-1 drugs and SGLT2 inhibitors have proven cardiovascular benefits for type 2 diabetes — but this new JACC study suggests that comparing individual medications within each class, not just the classes overall, may reveal meaningful real-world differences for heart protection.
What This Could Mean for Patients on GLP-1 Medications
If you are currently taking a GLP-1 medication like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), this research is a reminder that your drug choice may carry specific cardiovascular implications beyond blood sugar or weight management. Historically, large trials have shown GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events — including heart attack and stroke — in high-risk patients with type 2 diabetes.
The emerging focus on individual agents, rather than broad drug classes, could eventually help doctors make more personalized prescribing decisions based on a patient's specific heart risk profile.
What to Watch Next
The full results and data from this study were not available in the published abstract reviewed for this article. As the complete findings become more widely available, watch for:
- Whether specific GLP-1 agents outperform specific SGLT2 inhibitors — or vice versa — in real-world heart outcomes
- Any subgroup findings related to obesity, heart failure, or kidney disease
- Whether updated clinical guidelines from cardiology or diabetes organizations incorporate these comparisons into prescribing recommendations
Frequently Asked Questions
As always, if you have questions about how your current GLP-1 medication affects your heart health — or whether an SGLT2 inhibitor might be appropriate for you — speak with your prescriber or a cardiologist who can review your full medical history and help you make an informed, personalized decision.
- Peer-reviewed journal article, 'Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus,' Journal of the American College of Cardiology, date not specified.